SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-focused, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN® (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant . SciClone’s pipeline of drug ... More »

 Corporate Presentation

Recent Releases

Mar 2, 2010
SciClone Reports Financial Results for the Fourth Quarter and Year End 2009 and Provides Commercial and Pipeline Updates

Mar 1, 2010
SciClone Pharmaceuticals to Present at Three Investor Conferences in March

View all releases »

Events & Presentations

Mar 16, 2010 at 11:00 AM PT
Roth Growth Stock Conference

Mar 9, 2010 at 3:45 PM ET
Cowen Healthcare Conference

View all events & presentations »

Stock Chart
3 Mo.   6 Mo.   1 Yr.
Stock Quote
SciClone Pharmaceuticals, Inc.
Price:	3.80
Change:	+ 0.10
Day High:	3.85
Day Low:	3.70
Volume:	535,000
Delayed at least 20 minutes. Provided by eSignal.